A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma-Reference-Cited by-同舟云学术

A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma

Published:2012-02 Issue:2 Volume:23 Page:415-420
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Zinzani P.L.,Tani M.,Pulsoni A.,De Renzo A.,Stefoni V.,Broccoli A.,Montini G.C.,Fina M.,Pellegrini C.,Gandolfi L.,Cavalieri E.,Torelli F.,Scopinaro F.,Argnani L.,Quirini F.,Derenzini E.,Rossi M.,Pileri S.,Fanti S.,Baccarani M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/2/415/553357/mdr145.pdf

Reference30 articles.

1. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study;Jones;Cancer,1983

2. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin’s lymphoma;Hagenbeek;J Clin Oncol,2006

3. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy;Czuczman;J Clin Oncol,1999

4. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma;Marcus;J Clin Oncol,2008

5. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioimmunotherapy;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

2. Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study;Annals of Hematology;2023-03-30

3. Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials;Cancers;2021-11-07

4. Adverse events of radioimmunotherapy for non-Hodgkin lymphoma: A systematic review and meta-analysis;Leukemia Research;2021-09

5. Consolidation with 90 Yttrium‐ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma;Hematological Oncology;2020-10-07